Scientific American: If scientists had a test to confirm Alzheimer’s disease, would that have changed the outcome for some treatments that failed to pass scientific muster in clinical trials? Would such a test open doors for future treatments? Alzheimer’s researchers hoping to explore these questions had mixed reactions last week after Medicare recommended that the national health plan for the elderly and disabled only pay for a controversial $3,000 test that detects brain plaque linked to Alzheimer’s in several specific instances—including clinical trials that seek better treatment for the disease.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now